Patents by Inventor Elizabeth FRANKS

Elizabeth FRANKS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Exon skipping compositions for treating muscular dystrophy
    Patent number: 11932851
    Abstract: Antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon 44 skipping are described.
    Type: Grant
    Filed: December 22, 2020
    Date of Patent: March 19, 2024
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Richard K. Bestwick, Diane Elizabeth Frank
  • p110-delta inhibitors treat and prevent autoimmunity while sparing the ability to mount an immune response to exogenous immunogens
    Patent number: 11701361
    Abstract: Methods of using a phosphoinositide 3-kinase p110-delta inhibitor to treat, delay the onset, or slow the progression of an autoimmune disease or disorder in a subject, without suppressing the subject's B cell responses to exogenous antigens or rendering the subject immunocompromised, as well as pharmaceutical compositions containing phosphoinositide 3-kinase p110-delta inhibitors in amounts suitable for convenient and accurate administration within these therapeutic methods.
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: July 18, 2023
    Assignees: NATIONAL INSTITUTES OF HEALTH (NCH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT NIH DIVISION OF EXTRAMURAL INVENTIONS AND TECHNOLOGY RESOURCES (DEITR), THE REGENTS OF THE UNIVERSITY OF COLORADO
    Inventors: John Cambier, Elizabeth Franks
  • EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
    Publication number: 20230104708
    Abstract: Antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon 53 skipping are described.
    Type: Application
    Filed: May 11, 2022
    Publication date: April 6, 2023
    Applicant: Sarepta Therapeutics, Inc.
    Inventors: Richard K. BESTWICK, Diane Elizabeth FRANK
  • EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
    Publication number: 20220364093
    Abstract: Antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon 53 skipping are described.
    Type: Application
    Filed: June 3, 2022
    Publication date: November 17, 2022
    Applicant: Sarepta Therapeutics, Inc.
    Inventors: Richard K. BESTWICK, Diane Elizabeth FRANK
  • EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
    Publication number: 20220259592
    Abstract: Antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon 53 skipping are described.
    Type: Application
    Filed: October 11, 2021
    Publication date: August 18, 2022
    Applicant: Sarepta Therapeutics, Inc.
    Inventors: Richard K. BESTWICK, Diane Elizabeth FRANK
  • Processes for preparing oligomers
    Patent number: 11384105
    Abstract: Provided herein are processes for preparing an oligomer (e.g., a morpholino oligomer). The synthetic processes described herein may be advantageous to scaling up oligomer synthesis while maintaining overall yield and purity of a synthesized oligomer.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: July 12, 2022
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Baozhong Cai, Mitchell Martini, Ross Shimabuku, Katie Thomas, Diane Elizabeth Frank, Richard K. Bestwick
  • EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
    Publication number: 20220056442
    Abstract: Antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon 44 skipping are described.
    Type: Application
    Filed: April 19, 2021
    Publication date: February 24, 2022
    Inventors: Richard K. BESTWICK, Diane Elizabeth FRANK, Frederick Joseph SCHNELL
  • PROCESSES FOR PREPARING OLIGOMERS
    Publication number: 20210198296
    Abstract: Provided herein are processes for preparing an oligomer (e.g., a morpholino oligomer). The synthetic processes described herein may be advantageous to sealing up oligomer synthesis while maintaining overall yield and parity of a synthesized oligomer.
    Type: Application
    Filed: November 16, 2020
    Publication date: July 1, 2021
    Applicant: Sarepta Therapeutics, Inc.
    Inventors: Baozhong CAI, Mitchell MARTINI, Ross SHIMABUKU, Katie THOMAS, Diane Elizabeth FRANK, Richard K. BESTWICK
  • EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY
    Publication number: 20210187003
    Abstract: Antisense oligomers complementary to a selected target site in the human dystrophin gene to induce exon 45 skipping are described.
    Type: Application
    Filed: July 28, 2020
    Publication date: June 24, 2021
    Inventors: Diane Elizabeth FRANK, Richard K. BESTWICK
  • EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
    Publication number: 20210180064
    Abstract: Antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon 44 skipping are described.
    Type: Application
    Filed: December 22, 2020
    Publication date: June 17, 2021
    Inventors: Richard K. BESTWICK, Diane Elizabeth FRANK
  • P110-DELTA INHIBITORS TREAT AND PREVENT AUTOIMMUNITY WHILE SPARING THE ABILITY TO MOUNT AN IMMUNE RESPONSE TO EXOGENOUS IMMUNOGENS
    Publication number: 20210069197
    Abstract: Methods of using a phosphoinositide 3-kinase p110-delta inhibitor to treat, delay the onset, or slow the progression of an autoimmune disease or disorder in a subject, without suppressing the subject's B cell responses to exogenous antigens or rendering the subject immunocompromised, as well as pharmaceutical compositions containing phosphoinositide 3-kinase p110-delta inhibitors in amounts suitable for convenient and accurate administration within these therapeutic methods.
    Type: Application
    Filed: January 7, 2019
    Publication date: March 11, 2021
    Inventors: John CAMBIER, Elizabeth FRANKS
  • Exon skipping compositions for treating muscular dystrophy
    Patent number: 10907154
    Abstract: Antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon 44 skipping are described.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: February 2, 2021
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Richard K. Bestwick, Diane Elizabeth Frank
  • Processes for preparing oligomers
    Patent number: 10875880
    Abstract: Provided herein are processes for preparing an oligomer (e.g., a morpholino oligomer). The synthetic processes described herein may be advantageous to scaling up oligomersynthesis while maintaining overall yield and purity of a synthesized oligomer.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: December 29, 2020
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Baozhong Cai, Mitchell Martini, Ross Shimabuku, Katie Thomas, Diane Elizabeth Frank, Richard K. Bestwick
  • EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
    Publication number: 20200339985
    Abstract: Antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon 53 skipping are described.
    Type: Application
    Filed: December 4, 2019
    Publication date: October 29, 2020
    Applicant: Sarepta Therapeutics, Inc.
    Inventors: Richard K. BESTWICK, Diane Elizabeth FRANK
  • EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
    Publication number: 20200040336
    Abstract: Antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon 53 skipping are described.
    Type: Application
    Filed: March 19, 2019
    Publication date: February 6, 2020
    Applicant: Sarepta Therapeutics, Inc.
    Inventors: Richard K. BESTWICK, Diane Elizabeth FRANK
  • PROCESSES FOR PREPARING OLIGOMERS
    Publication number: 20200040020
    Abstract: Provided herein are processes for preparing an oligomer (e.g., a morpholino oligomer). The synthetic processes described herein may be advantageous to scaling up oligomersynthesis while maintaining overall yield and purity of a synthesized oligomer.
    Type: Application
    Filed: May 24, 2017
    Publication date: February 6, 2020
    Inventors: Bao CAI, Mitchell MARTINI, Ross SHIMABUKU, Katie THOMAS, Diane Elizabeth FRANK, Richard K. BESTWICK
  • EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
    Publication number: 20190330624
    Abstract: Antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon 44 skipping are described.
    Type: Application
    Filed: December 7, 2018
    Publication date: October 31, 2019
    Inventors: Richard K. Bestwick, Diane Elizabeth Frank, Fred Joseph Schnell
  • EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY
    Publication number: 20190262375
    Abstract: Antisense oligomers complementary to a selected target site in the human dystrophin gene to induce exon 45 skipping are described.
    Type: Application
    Filed: June 29, 2017
    Publication date: August 29, 2019
    Inventors: Diane Elizabeth FRANK, Richard K. BESTWICK
  • EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
    Publication number: 20190177724
    Abstract: Antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon 44 skipping are described.
    Type: Application
    Filed: December 14, 2018
    Publication date: June 13, 2019
    Inventors: Richard K. BESTWICK, Diane Elizabeth FRANK
  • EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
    Publication number: 20180016574
    Abstract: Antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon 44 skipping are described.
    Type: Application
    Filed: February 13, 2017
    Publication date: January 18, 2018
    Inventors: Richard K. BESTWICK, Diane Elizabeth FRANK